Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell
malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms.
Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic
leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.
Keywords: CLL, chemotherapy, BTK, BCR, tyrosine, kinase.
Rights & PermissionsPrintExport